Read as much as you want on, anywhere and anytime, for just 99¢.

Mass. Movers

Firm sets a $22 price target for Verastem

Verastem’s cancer research focuses on stem cells.

Kayana Szymczak for the Globe/File

Verastem’s cancer research focuses on stem cells.

Continue reading below

Analysts at Cantor Fitzgerald began coverage of Cambridge-based Verastem Inc. with a “buy” rating and a $22 price target. Verastem is developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis, according to the company. Verastem is developing small-molecule inhibitors of signaling pathways that are critical to cancer stem cell survival.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of